Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Novel therapeutic strategies for non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma and mantle cell lymphoma, are transforming clinical management. Experts evaluate the integration of CD79b-targeted agents like Polatuzumab Vedotin and CD19-directed therapies, emphasizing their efficacy in relapsed settings and potential for chemo-free frontline regimens. The discussion highlights the shift toward BTK inhibitor-based triplets in mantle cell lymphoma, noting that these combinations may eliminate the need for autologous stem cell transplantation in younger patients. Panelists address critical challenges, including the management of treatment-emergent toxicities, the role of molecular profiling in patient selection, and the sequencing of bispecific antibodies and CAR T-cell therapy. Clinical case studies underscore the importance of nuanced decision-making regarding CNS prophylaxis and the management of high-risk, elderly populations, where balancing efficacy with cumulative toxicity remains paramount.